Cover Image

Pentostatin and purine analogs for indolent lymphoid malignancies

Pentostatin has been shown to be active in a variety of B- and T-cell malignancies. The drug is a tight inhibitor of adenosine deaminase, a key degradative enzyme of purine metabolism present in all human tissues, with the highest levels found in the lymphoid system. Early clinical trials indicated...

Full description

Saved in:
Bibliographic Details
Main Authors: Ho, Anthony Dick (Author) , Hensel, Manfred (Author)
Format: Article (Journal)
Language:English
Published: 24 Mar 2006
In: Future oncology
Year: 2006, Volume: 2, Issue: 2, Pages: 169-183
ISSN:1744-8301
DOI:10.2217/14796694.2.2.169
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/14796694.2.2.169
Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/14796694.2.2.169
Get full text
Author Notes:Anthony D. Ho, Manfred Hensel

MARC

LEADER 00000caa a22000002c 4500
001 1776279255
003 DE-627
005 20230428085621.0
007 cr uuu---uuuuu
008 211105s2006 xx |||||o 00| ||eng c
024 7 |a 10.2217/14796694.2.2.169  |2 doi 
035 |a (DE-627)1776279255 
035 |a (DE-599)KXP1776279255 
035 |a (OCoLC)1341423388 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
245 1 0 |a Pentostatin and purine analogs for indolent lymphoid malignancies  |c Anthony D. Ho, Manfred Hensel 
264 1 |c 24 Mar 2006 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.11.2021 
520 |a Pentostatin has been shown to be active in a variety of B- and T-cell malignancies. The drug is a tight inhibitor of adenosine deaminase, a key degradative enzyme of purine metabolism present in all human tissues, with the highest levels found in the lymphoid system. Early clinical trials indicated that this agent was highly active in acute lymphoblastic leukemias with high intracellular adenosine deaminase levels. Relatively high doses of the drug were needed, which was associated with severe adverse events. Through the efforts of a few investigators, better tolerated, low-dose regimens have been shown to be extremely active in lymphoproliferative diseases with very low intracellular adenosine deaminase levels such as hairy cell leukemia, B- and T-cell chronic leukemias, T-cell cutaneous lymphomas and low-grade non-Hodgkin lymphomas. Clinical as well as experimental data have indicated that this drug induces lymphocyte-specific cytotoxicity, and myelosuppressive adverse events have been minimal. Although all the purine analogs have shown similar activity, the advantage of pentostatin is the relatively specific cytotoxicity against lymphocytes, which permits treatment even in patients with severe cytopenias. Although no direct comparisons of the purine analogs have been performed, pentostatin may be preferred due to this property. 
650 4 |a chronic lymphocytic leukemia 
650 4 |a graft-versus-host disease 
650 4 |a hairy cell leukemia 
650 4 |a low-grade lymphomas 
650 4 |a lymphoplasmacytic lymphomas 
650 4 |a lymphoproliferative diseases 
650 4 |a pentostatin (2´-deoxycoformycin) 
650 4 |a purine degradative enzymes 
700 1 |a Hensel, Manfred  |d 1964-  |e VerfasserIn  |0 (DE-588)1065849729  |0 (DE-627)816878307  |0 (DE-576)425541908  |4 aut 
773 0 8 |i Enthalten in  |t Future oncology  |d London : Taylor & Francis, 2005  |g 2(2006), 2, Seite 169-183  |h Online-Ressource  |w (DE-627)484405055  |w (DE-600)2184533-5  |w (DE-576)398100217  |x 1744-8301  |7 nnas  |a Pentostatin and purine analogs for indolent lymphoid malignancies 
773 1 8 |g volume:2  |g year:2006  |g number:2  |g pages:169-183  |g extent:15  |a Pentostatin and purine analogs for indolent lymphoid malignancies 
856 4 0 |u https://doi.org/10.2217/14796694.2.2.169  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.futuremedicine.com/doi/10.2217/14796694.2.2.169  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20211105 
993 |a Article 
994 |a 2006 
998 |g 1065849729  |a Hensel, Manfred  |m 1065849729:Hensel, Manfred  |d 910000  |d 910100  |e 910000PH1065849729  |e 910100PH1065849729  |k 0/910000/  |k 1/910000/910100/  |p 2  |y j 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1776279255  |e 3999397799 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"relHost":[{"id":{"zdb":["2184533-5"],"issn":["1744-8301"],"eki":["484405055"]},"title":[{"title":"Future oncology","title_sort":"Future oncology"}],"recId":"484405055","note":["Gesehen am 28.05.2024"],"language":["eng"],"origin":[{"publisherPlace":"London ; London","publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedKey":"2005","dateIssuedDisp":"2005-"}],"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2005 -"],"part":{"year":"2006","volume":"2","issue":"2","text":"2(2006), 2, Seite 169-183","extent":"15","pages":"169-183"},"disp":"Pentostatin and purine analogs for indolent lymphoid malignanciesFuture oncology"}],"physDesc":[{"extent":"15 S."}],"origin":[{"dateIssuedDisp":"24 Mar 2006","dateIssuedKey":"2006"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Anthony D. Ho, Manfred Hensel"]},"id":{"eki":["1776279255"],"doi":["10.2217/14796694.2.2.169"]},"title":[{"title":"Pentostatin and purine analogs for indolent lymphoid malignancies","title_sort":"Pentostatin and purine analogs for indolent lymphoid malignancies"}],"person":[{"display":"Ho, Anthony Dick","role":"aut","given":"Anthony Dick","family":"Ho"},{"display":"Hensel, Manfred","role":"aut","given":"Manfred","family":"Hensel"}],"note":["Gesehen am 05.11.2021"],"recId":"1776279255"} 
SRT |a HOANTHONYDPENTOSTATI2420 

Similar Items